Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML

Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
angilma1

/by

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
arcticnovartis

  • There is currently no evidence-based treatment for the smallest babies with malaria
  • The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg
  • The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review

Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from the

/by

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
arcticnovartis

  • Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancer
  • Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet need
  • Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications

Basel, May 2, 2024 – Novartis today announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage bio

/by

From black holes to AI driven drug discovery – collaboration wins the day

From black holes to AI driven drug discovery – collaboration wins the day
metzgma4

/by

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
arcticnovartis

  • Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients
  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease
/by

Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht

Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR

/by

Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024

Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024
arcticnovartis

Annonce événementielle au sens de l’art. 53 RC

Résultats du premier trimestre (T1)

/by

Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised

Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis Financial Results – Q1 2024

Novartis Financial Results – Q1 2024
angilma1

/by

Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)

Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
arcticnovartis

  • Positive CHMP opinion based on robust Phase III data, including APPLY-PNH, demonstrating superior hemoglobin improvement in the absence of transfusions with Fabhalta compared to anti-C5 therapy1-5
/by